These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20413022)

  • 21. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lactic acidosis in HIV-I infected patients receiving antiretroviral therapy.
    Patel AK; Patel K; Patel J
    J Assoc Physicians India; 2004 Aug; 52():666-9. PubMed ID: 15847366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.
    Boulassel MR; Morales R; Murphy T; Lalonde RG; Klein MB
    J Med Virol; 2006 Sep; 78(9):1158-63. PubMed ID: 16847953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic and morphologic complications of HIV infection.
    Eid AJ; Orenstein R
    J Med Liban; 2006; 54(2):97-105. PubMed ID: 17087001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
    Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
    HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients.
    Veloso S; Peraire J; Viladés C; López-Dupla M; Escoté X; Olona M; Garcia-Pardo G; Gómez-Bertomeu F; Soriano A; Sirvent JJ; Vidal F
    Curr Pharm Des; 2010 Oct; 16(30):3379-89. PubMed ID: 20687887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The problems faced when assessing the prevalence and incidence of antiretroviral-related toxicities.
    Smith CJ; Sabin CA
    Antivir Ther; 2004 Dec; 9(6):865-78. PubMed ID: 15651745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Common adverse effects of antiretroviral therapy for HIV disease.
    Reust CE
    Am Fam Physician; 2011 Jun; 83(12):1443-51. PubMed ID: 21671545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Metabolic changes in HIV infected patient].
    Castelo Filho A; Abrão P
    Arq Bras Endocrinol Metabol; 2007 Feb; 51(1):5-7. PubMed ID: 17435849
    [No Abstract]   [Full Text] [Related]  

  • 30. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The long-term consequences of antiretroviral therapy: a review.
    Boyd M; Reiss P
    J HIV Ther; 2006 Jun; 11(2):26-35. PubMed ID: 16981593
    [No Abstract]   [Full Text] [Related]  

  • 32. Mitochondrial toxicity.
    Scoular A
    J HIV Ther; 2001 Mar; 6(1):1-3. PubMed ID: 11501195
    [No Abstract]   [Full Text] [Related]  

  • 33. Increasing burden of liver disease in patients with HIV infection.
    Joshi D; O'Grady J; Dieterich D; Gazzard B; Agarwal K
    Lancet; 2011 Apr; 377(9772):1198-209. PubMed ID: 21459211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver disease in the HIV-infected individual.
    Price JC; Thio CL
    Clin Gastroenterol Hepatol; 2010 Dec; 8(12):1002-12. PubMed ID: 20851211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lactic acidosis in HIV patients receiving highly active antiretroviral therapy.
    Chow YW; Leong CL; Chow HL; Hooi LS
    Med J Malaysia; 2007 Mar; 62(1):78-80. PubMed ID: 17682581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic complications of HIV therapy.
    Chow DC; Day LJ; Souza SA; Shikuma CM
    IAPAC Mon; 2006 Sep; 12(9):302-17. PubMed ID: 17378067
    [No Abstract]   [Full Text] [Related]  

  • 37. [Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection].
    Polo R; José Galindo M; Martínez E; Alvarez J; Arévalo JM; Asensi V; Cánoves D; Cáncer E; Collazos J; Estrada V; Gómez-Candela C; Johnston S; Locutura J; López-Aldeguer J; Lozano F; Miralles C; Muñoz-Sanz A; Ortega E; Pascua J; Pedrol E; Pulido F; San Martín M; Sanz J; Viciana P; Chamorro L;
    Enferm Infecc Microbiol Clin; 2006 Feb; 24(2):96-117. PubMed ID: 16545318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Management of antiretroviral drug toxicity].
    Domingo P; Lozano F
    Enferm Infecc Microbiol Clin; 2011; 29(7):535-44. PubMed ID: 21324557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of common chronic metabolic complications in HIV-infected patients.
    Bader MS; Kelly DV
    Postgrad Med; 2008 Nov; 120(4):17-27. PubMed ID: 19020362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.
    Núñez M
    Hepatology; 2010 Sep; 52(3):1143-55. PubMed ID: 20812358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.